ANAVEX LIFE SCIENCES CORP. financial data

Symbol
AVXL on Nasdaq
Location
New York, NY
Fiscal year end
30 September
Latest financial report
10-K - Q3 2025 - 25 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 12.84 % +36.1%
Return On Equity -46.79 % -41.6%
Return On Assets -41.46 % -37.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 89,348,107 shares +5.3%
Common Stock, Shares, Outstanding 86,668,521 shares +2.2%
Entity Public Float 708,000,000 USD +71.8%
Common Stock, Value, Issued 87,000 USD +2.4%
Weighted Average Number of Shares Outstanding, Basic 85,289,447 shares +2.2%
Weighted Average Number of Shares Outstanding, Diluted 85,289,447 shares +2.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 37,592,000 USD -10.1%
General and Administrative Expense 13,816,000 USD +25.2%
Operating Income (Loss) -51,408,000 USD +2.8%
Nonoperating Income (Expense) 5,031,000 USD -49.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43,002,000 USD +9.5%
Net Income (Loss) Attributable to Parent -46,377,000 USD -7.8%
Earnings Per Share, Basic 0 USD/shares -3.8%
Earnings Per Share, Diluted 0 USD/shares -3.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 102,577,000 USD -22.4%
Assets 103,815,000 USD -23.4%
Accounts Payable, Current 4,249,000 USD -55.9%
Accrued Liabilities, Current 3,892,000 USD -19.5%
Liabilities 8,946,000 USD -41.5%
Retained Earnings (Accumulated Deficit) -382,448,000 USD -13.8%
Stockholders' Equity Attributable to Parent 94,869,000 USD -21.1%
Liabilities and Equity 103,815,000 USD -23.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12,120,000 USD -65.6%
Net Cash Provided by (Used in) Financing Activities 708,000 USD +11%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 86,668,521 shares +2.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 102,577,000 USD -22.4%
Deferred Tax Assets, Valuation Allowance 108,492,000 USD +17.6%
Deferred Tax Assets, Gross 20,700,000 USD +37.1%
Deferred Tax Assets, Operating Loss Carryforwards 54,752,000 USD +13.7%
Current Income Tax Expense (Benefit) 59,000 USD -79%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Share-based Payment Arrangement, Expense 11,500,000 USD +22.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%